Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
Adequate glutathione levels help ward off many aging-related diseases, as low levels are often associated with a higher incidence of cancer, diabetes, and heart disease
GDFs GDF15 improves metabolic parameters, including insulin sensitivity and glycemic control, in obesity models via glial cell line-derived neurotrophic factor (GDNF) family receptor like (GFRAL) receptor signaling (Sjoberg et al
Moreover, all LMNA transgenic adult fish, except LMNA (E358K), display weaker muscle endurance than LMNA (WT) measured by swimming tunnel
Moreover, almost all of this research comes from a handful of high-income countries, even as uptake of these drugs is increasing globally and the burden of cancer has disproportionately grown in lower-income countries
CJC-1295 + Ipamorelin Synergistic combination for enhanced GH release
